JavaScript is disabled. Please enable to continue!

Mobile search icon
Eurofins >> Media Centre >> 2014-01-16

Eurofins reinforces its pharmaceutical Quality Control capability with the acquisition of IDmyk

Sidebar Image

Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, announces the acquisition of IDmyk, a leading laboratory specialized in the areas of detection, identification and molecular typing of microorganisms for the pharmaceutical industry. The acquisition reinforces Eurofins' pharmaceutical quality control (QC) offering, and complements its existing capabilities in microbiological analysis.

Since 2000, IDmyk has developed market-leading expertise in establishing the genetic identity of microorganisms to support product or process-related investigations. As such, IDmyk has the largest validated proprietary database for Good Manufacturing Practice (GMP) identification service in the industry. These, combined with Eurofins' existing identification capabilities, strengthen the Group's pharmaceutical QC service offering. Furthermore, rolling-out the methods to the relevant laboratories across the Group network will allow Eurofins to benefit from reduced costs given the use of proprietary reagents in the processes.

IDmyk, based in Lyon, France, with revenues of less than EUR 2m currently, will benefit from Eurofins' focus on innovation, with substantial resources for research and development. For example, as one of the global leaders in genomics services, Eurofins has considerable expertise in the area of next-generation sequencing, which may be used for faster, more precise identification of organisms at the strain level. In addition, IDmyk will have access to Eurofins' wide portfolio of products and services, as well as access to the Group's clients.

For more information, please contact:

Dr. Gautier Decock

Eurofins Pharma Quality Control

Phone: +33 1 69 10 88 80

E-mail: gautierdecock@eurofins.com

Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics and central laboratory services.

With over 15,000 staff in more than 190 laboratories across 37 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.